Lyell Immunopharma Inc.
(LYEL)
undefined
undefined%
At close: undefined
0.71
3.44%
Pre-market Dec 16, 2024, 04:14 AM EST
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to
free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Net Income | -234.63M | -183.12M | -250.22M | -204.47M | -129.38M |
| Depreciation & Amortization | 20.25M | 18.02M | 13.62M | 4.29M | 1.26M |
| Stock-Based Compensation | 47.08M | 81.92M | 62.20M | 33.26M | 15.73M |
| Other Working Capital | 1.96M | -82.68M | 3.92M | -58.00K | 109.10M |
| Other Non-Cash Items | 183.00K | -6.68M | 4.62M | 11.99M | 42.57M |
| Deferred Income Tax | - | 2.32M | 39.51M | -5.61M | -1.52M |
| Change in Working Capital | 3.42M | -82.02M | 4.01M | -336.00K | 110.81M |
| Operating Cash Flow | -163.69M | -169.56M | -126.25M | -160.87M | 39.47M |
| Capital Expenditures | -2.69M | -24.28M | -65.50M | -51.48M | -16.05M |
| Acquisitions | -186.73M | -12.74M | 673.47M | - | - |
| Purchase of Investments | -476.88M | -406.32M | -673.47M | -43.45M | -34.00M |
| Sales Maturities Of Investments | 663.61M | 419.05M | 617.40M | 686.32M | 238.46M |
| Other Investing Acitivies | 186.73M | 12.74M | -673.47M | -864.91M | -610.84M |
| Investing Cash Flow | 184.05M | -11.54M | -121.57M | -273.52M | -422.43M |
| Debt Repayment | - | - | - | - | - |
| Common Stock Repurchased | -457.00K | -461.00K | - | -16.05M | -185.00K |
| Dividend Paid | - | - | - | - | - |
| Other Financial Acitivies | 1.74M | 10.63M | 9.44M | 488.60M | 351.34M |
| Financial Cash Flow | 1.74M | 10.63M | 401.24M | 476.79M | 351.16M |
| Net Cash Flow | 22.10M | -170.46M | 153.42M | 42.40M | -31.80M |
| Free Cash Flow | -166.38M | -193.83M | -191.75M | -212.35M | 23.43M |